Pharmaceutically active compounds and methods of use

Details Pharmaceutically active compounds and methods of use Pharmaceutically active compounds and methods of use

2006-09-05

2006-09-05

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S048000, C549S044000, C549S043000

Reexamination Certificate

active

07101905

ABSTRACT:
New fused thiophene compounds are provided and methods of using those compounds for a variety of therapeutic indications. Compounds of the invention are particularly useful for treatment of neuropathic pain.

REFERENCES:
patent: 5691318 (1997-11-01), Sollevi
patent: 5939432 (1999-08-01), Baraldi
patent: 6066658 (2000-05-01), Yasuma et al.
patent: 6156787 (2000-12-01), Broughton et al.
Copy of International Search Report dated Aug. 22, 2003, issued in corresponding PCT Patent Application No.: PCT/US02/09943.
Bruns, et al., “Structure-Activity Relationships for Enhancement of Adenosine A1Receptor Binding by 2-Amino-3-benzoylthiophenes,” Molecular Pharmacology 38:950-958 (1990).
van der Klein, “Allosteric Modulation of the Adenosine A1 Receptor. Synthesis and Biological Evaluation of Novel 2-Amino-3-benzoylthiophenes as Allosteric Enhancers of Agonist Binding,” J. Med. Chem 42:3629-3635 (1999).
Baral di, et al., “Synthesis and Biological Effects of a New Series of 2-Amino-3-benzoylthiophenes as Allosteric Enhancers of A1-Adenosine Receptor,” Bioorganic & Medicinal Chemistry Letters 10:1953-1957 (2000).
Bruns, et al., “Allosteric Enhancement of Adenosine A1Receptor Binding and Function by 2-Amino-3-benzoylthiophenes,” Molecular Pharmacology 38:939-949 (1990).
Leung, et al., “Enhancement of Adenosine A1Receptor Functions by Benzoylthiophenes in Guinea Pig Tissues In Vitro,” Arch. Pharmacol. 352:206-212 (1995).
Tranberg, et al., “2-Amino-3-aroly-4,5-alkylthiophenes: Agonist Allosteric Enhancers at Human A1Adenosine Receptors,” J. Med. Chem. 45:382-389 (2002).
Kourounakis, et al., “Elucidation of Structures-Activity Relationships of 2-Amino-3-benzoylthiophenes: Study of Their Allosteric Enhancing vs. Antagonistic Activity on Adenosine A1Receptors,” Drug Development Research 49:227-237 (2000).
Gomes, et al., “Intrathecal Adenosine Interacts with a Spinal Noradrenergic System to Produce Antinociception in Nerve-Injured Rats,” Anesthesiology 91;1072-1079 (1999).
Zhu, et al., “A-134974: a novel adenosine kinase inhibitor, relieves tactile allodyniz via spinal sites of action in peripheral nerve injured rats,” Brain Research 905:104-110 (2001).
Suzuki, et al., “The effect of ABT-702, a novel adenosine kinase inhibitor, on the response of spinal neurons following carrageenan inflammation and peripheral nerve injury,” British Journal of Pharmacology 132:1615-1623 (2001).
Lynch, et al., “An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain,” European Journal of Pharmacology 364:141-146 (1999).
Kowaluk, et al., “ABT-702(4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine),A Novel Orally Effective Adenosine Kinase Inhibitor with Analgesic and Anti-Inflammatory Properties. II. In Vivo Characterization in the Rat,” The Journal of Pharmacology and Experimental Therapeutics 295:1165-1174 (2000).
Holmgren, et al., “Characterization of the antinociceptive effects of some adenosine analogues in the rat,” Arch. Pharmacol. 334:290-293 (1986).
Sollevi, et al., “Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain,” Pain 61:155-158 (1995).
Belfrage, et al., “Systemic Adenozine Infusion Alleviates Spontaneous and Stimulus Evoked Pain in Patients with Peripheral Neuropathic Pain,” Anesth. Analg. 81:713-717 (1995).
Sjölund, et al., “Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: a multi-centre, placebo-controlled study,” European Journal of Pain 5:199-207 (2001).
Sjölund, et al., “Adenosine Reduces Secondary Hyperalgesia in Two Human Models of Cutaneous Inflammatory Pain,” Anesth. Analg. 88:605-610 (1999).
Salter, et al., “Evidence that Adenosine Mediates the Depression of Spinal Dorsal Horn Neurons Induced by Peripheral Vibration in the Cat,” Neruoscience 22:631-650 (1987).
Lavand'homme, et al., “Exogenous and endogenous adenosine enhance the spinal antiallodynic effects of morphine in a rat model of neuropathic pain,” Pain 80:31-36 (1999).
Belfrage, et al., “The Safety and Efficacy of Intrathecal Adenosine in Patients with Chronic Neuropathic Pain,” Anesth. Analg. 89:136-142 (1999).
Kollias-Baker, et al., “Agonist-Independent Effect of an Allosteric Enhancer of the A1Adenosine Receptor in CHO Cells Stably Expressing the Recombinant Human A1Receptor,” The Journal of Pharmacology and Experimental Therapeutics 281:761-768 (1997).
Shryock, et al., “Inverse Agonists and Neutral Antagonists of Recombinant Human A1Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells,” Molecular Pharmacology 53:886-893 (1998).
Narcisse, et al. “Communication courte: Synthèse et pharmacology des derives de l'amino-2 éthoxycarbonyl-3 phényl-4 thiophène,,” Eur. J. Med. Chem.—Chimica Therapeutica 15:563-565 (1980).
Gu pta, et al., “New total synthesis of(±)-herbetene, (±)-β-herbertenol and(±)-herbertenediol,” Tetrahedron Letters 41:7563-7566 (2000).

Affiliated with

Also associated with

Rating

Pharmaceutically active compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active compounds and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3533348